scholarly journals 287P Burden of illness of HER2+ in metastatic breast cancer (MBC) patients: A systematic literature review (SLR)

2021 ◽  
Vol 32 ◽  
pp. S490
Author(s):  
G. Vondeling ◽  
T. Harding ◽  
A. Seddik ◽  
K. Bakker ◽  
R. Velikanova
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Literature Review ◽  
Systematic Literature Review ◽  
Burden Of Illness ◽  
Metastatic Breast

A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2− Metastatic Breast Cancer

2020 ◽  
Vol 20 (3) ◽  
pp. e232-e243 ◽  
Author(s):  
Lea E. Mollon ◽  
Elizabeth J. Anderson ◽  
Joni L. Dean ◽  
Terri L. Warholak ◽  
Ayal Aizer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Literature Review ◽  
Systematic Literature Review ◽  
Predictive Value ◽  
Metastatic Breast ◽  
Pik3ca Mutations

A systematic literature review of the clinical prognosis of HR+/HER2- advanced or metastatic breast cancer with and without PIK3CA mutation.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e13037-e13037 ◽  
Author(s):  
Elizabeth J Anderson ◽  
Lea Mollon ◽  
Joni L Dean ◽  
Alejandra Aguilar ◽  
Lisa E. Davis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Literature Review ◽  
Systematic Literature Review ◽  
Pik3ca Mutation ◽  
Metastatic Breast ◽  
Clinical Prognosis

scholarly journals CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies

2021 ◽  
Author(s):  
Nadia Harbeck ◽  
Meaghan Bartlett ◽  
Dean Spurden ◽  
Becky Hooper ◽  
Lin Zhan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Literature Review ◽  
Systematic Literature Review ◽  
Real World ◽  
Metastatic Breast ◽  
Improved Outcomes ◽  
Real World Evidence

Background: This review aims to qualitatively summarize the published real-world evidence (RWE) for CDK4/6 inhibitors (CDK4/6i) approved for treating HR+, HER2-negative advanced/metastatic breast cancer (HR+/HER2- a/mBC). Materials & methods: A systematic literature review was conducted to identify RWE studies of CDK4/6i in HR+/HER2- a/mBC published from 2015 to 2019. Results: This review identified 114 studies, of which 85 were only presented at scientific conferences. Most RWE studies investigated palbociclib and demonstrated improved outcomes. There are limited long-term and comparative data between CDK4/6i and endocrine monotherapy, and within the CDK4/6i class. Conclusion: Available RWE suggests that CDK4/6i are associated with improved outcomes in HR+/HER2- a/mBC, although additional studies with longer follow-up periods are needed.

BP52 IS THERE A DIFFERENT TREATMENT RESPONSE BETWEEN VISCERAL AND NON-VISCERAL METASTATIC BREAST CANCER: A SYSTEMATIC LITERATURE REVIEW OF REGISTRATION TRIALS

The Breast ◽  
2015 ◽  
Vol 24 ◽  
pp. S39
Author(s):  
Rachel Würstlein ◽  
Maximilian Bardenhewer ◽  
Alexander König ◽  
Thomas Kolben ◽  
Caroline Gehring ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Literature Review ◽  
Treatment Response ◽  
Systematic Literature Review ◽  
Metastatic Breast

Orbitotemporal Bone Cyst of Metastatic Breast Cancer: Case Report and Literature Review

2019 ◽  
Vol 130 ◽  
pp. 267-270
Author(s):  
Yoshifumi Tao ◽  
Kenji Yagi ◽  
Hirotake Nishimura ◽  
Keijirou Hara ◽  
Shunji Matsubara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Literature Review ◽  
Bone Cyst ◽  
Metastatic Breast ◽  
Breast Cancer Case ◽  
Cancer Case
Sign in / Sign up

Export Citation Format

Share Document